Levi & Korsinsky, LLP announces that an EBS class action lawsuit has been filed on behalf of investors who purchased Emergent Biosolutions Inc. (EBS) securities between July 6, 2020, and March 31, 2021. For more on the EBS Lawsuit please contact us today.

According to the Emergent Bio lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Emergent’s Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent’s facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants’ public statements about Emergent’s ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.

TO LEARN MORE ABOUT THE EBS CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Emergent Bio you have until June 18, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com